Bioxyne Limited (ASX:BXN) Announces Revenue Growth Plans
Revenue Performance
Bioxyne Limited (ASX:BXN) has reported revenue of approximately A$12.5 million for the six months ending 31 December 2024, supporting its near-term growth objective of exceeding A$20 million in revenue. This aligns with the company’s strategy highlighted in the investor presentation on 18 November 2024.
Manufacturing Expansion
The company is set to commission a new manufacturing facility in January 2025. This expansion will double the current manufacturing capacity of Breathe Life Sciences (BLS), providing the foundation for increased production to meet growing demand.
Market Position and Contracts
Bioxyne has established a diverse customer base and has secured significant supply agreements, with estimated contracts worth A$36.5 million over the next two years. These projections are based on strong current performance and additional contracts beyond those announced previously in August and September 2024.
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.